AGEN Stock Analysis: Buy, Sell, or Hold?
AGEN - Agenus Inc.
$7.67
-0.42 (-5.19%)
▼
5d:
+7.27%
30d:
+28.26%
90d:
+146.62%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When AGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AGEN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AGEN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: AGEN is currently trading at $7.67, which is considered extended relative to its 30-day fair value range of $5.66 to $7.75. From a valuation perspective, the stock is trading at a discount (Forward PE: -127.8) compared to its historical average (5.1). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AGEN is in a strong uptrend. Immediate support is located at $6.42, while resistance sits at $8.73. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: AGEN scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.50 (+154.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AGEN is in a strong uptrend. Immediate support is located at $6.42, while resistance sits at $8.73. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: AGEN scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.50 (+154.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.66 -
$7.75
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
28.6%
Protect Your Profits
Holding AGEN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.2%)
- BULLISH: Trading 154.2% below Wall St target ($19.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.66 -
$7.75
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.42
Resistance Level
$8.73
Current Trend
Strong Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-127.83
Wall Street Target
$19.50
(+154.2%)
Revenue Growth (YoY)
34.4%
Profit Margin
69.3%
PE vs Historical
-127.8 vs 5.1
CHEAP
Share & Embed Analysis
Last updated: August 24, 2026 5:27 PM ET
Data refreshes hourly during market hours. Next update: 6:27 PM
Data refreshes hourly during market hours. Next update: 6:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 39 SELL |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 48 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 37 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 33 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$131 | 41 HOLD |
Advanced AGEN Option Strategies
Professional options setups generated by AI based on today's AGEN price and gamma walls.
